مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

379
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

229
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

3

Information Journal Paper

Title

LOW DOSE RIBAVIRIN FOR TREATMENT OF HEPATITIS C VIRUS INFECTED THALASSEMIA MAJOR PATIENTS, NEW INDICATIONS FOR COMBINATION THERAPY

Pages

  372-381

Abstract

 Background: Treatment guidelines contraindicate RIBAVIRIN for treatment of hepatitis C virus (HCV) infection in thalassemia major patients. nevertheless, the current evidence suggests that RIBAVIRIN might be tolerated by these patients.Objectives: Despite this evidence, low dose RIBAVIRIN combination therapy has not been compared with peginterferon monotherapy in these patients so far.Patients and Methods: Two hundred eighty thalassemia patients with detectable HCVRnA PCR ( ³ 50 IU/mL) and liver histology consistent with chronic HCV infection were selfassigned to receive PEGINTERFERON ALFA-2A (n = 81) monotherapy or its combination therapy with RIBAVIRIN, 600-800 mg QD, according to hemoglobin levels (n = 199). Treatment experienced patients were eligible for this study.Results: Sustained virological response (SVR) was significantly higher in patients who received RIBAVIRIN (51 % vs. 38 % P = 0.02). In multivariate regression, oR of RIBAVIRIN for prediction of SVR was 2.2 (95 % CI 1.24-3.91). The SVR was significantly higher in the RIBAVIRIN group in subgroups of patients with more than 24 years of age, elevated ALT, ferritin < 2006 ng/ mL, previous treatment failure, genotype 1, positive history of splenectomy, fibrosis score of 0-4 HAI and viral load < 600,000 IU/mL. Treatment discontinuations due to the safety concerns were comparable between the treatment groups (6.5 and 8 %). Furthermore, transfusion intervals were almost halved in patients who received low dose RIBAVIRIN.Conclusions: According to the present study, adult thalassemia patients with HCV infection can be treated successfully with low dose RIBAVIRIN. Hence, we strongly advise combination therapy in thalassemia patients with aforementioned clinical characteristics. Moreover, RIBAVIRIN does not seem to be beneficial in thalassemia patients below 18 years of age.

Cites

References

  • No record.

    • Cite

    APA: Copy

    TABATABAEI, SEYED VAHID, ALAVIAN, SEYED MOAYED, KESHVARI, MARYAM, BEHNAVA, BITA, MIRI, SEYYED MOHAMMAD, KARIMI ELIZEE, PEGAH, ZAMANI, FARHAD, AMINI KAFIABAD, SEDIGHEH, GHAREHBAGHIAN, AHMAD, HAJIBEIGY, BASHIR, & BAGHERI LANKARANI, KAMRAN. (2012). LOW DOSE RIBAVIRIN FOR TREATMENT OF HEPATITIS C VIRUS INFECTED THALASSEMIA MAJOR PATIENTS, NEW INDICATIONS FOR COMBINATION THERAPY. HEPATITIS MONTHLY, 12(6), 372-381. SID. https://sid.ir/paper/306515/en

    Vancouver: Copy

    TABATABAEI SEYED VAHID, ALAVIAN SEYED MOAYED, KESHVARI MARYAM, BEHNAVA BITA, MIRI SEYYED MOHAMMAD, KARIMI ELIZEE PEGAH, ZAMANI FARHAD, AMINI KAFIABAD SEDIGHEH, GHAREHBAGHIAN AHMAD, HAJIBEIGY BASHIR, BAGHERI LANKARANI KAMRAN. LOW DOSE RIBAVIRIN FOR TREATMENT OF HEPATITIS C VIRUS INFECTED THALASSEMIA MAJOR PATIENTS, NEW INDICATIONS FOR COMBINATION THERAPY. HEPATITIS MONTHLY[Internet]. 2012;12(6):372-381. Available from: https://sid.ir/paper/306515/en

    IEEE: Copy

    SEYED VAHID TABATABAEI, SEYED MOAYED ALAVIAN, MARYAM KESHVARI, BITA BEHNAVA, SEYYED MOHAMMAD MIRI, PEGAH KARIMI ELIZEE, FARHAD ZAMANI, SEDIGHEH AMINI KAFIABAD, AHMAD GHAREHBAGHIAN, BASHIR HAJIBEIGY, and KAMRAN BAGHERI LANKARANI, “LOW DOSE RIBAVIRIN FOR TREATMENT OF HEPATITIS C VIRUS INFECTED THALASSEMIA MAJOR PATIENTS, NEW INDICATIONS FOR COMBINATION THERAPY,” HEPATITIS MONTHLY, vol. 12, no. 6, pp. 372–381, 2012, [Online]. Available: https://sid.ir/paper/306515/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button